RFK Jr. on Rogan — peptides moving back to Category 1

A claim-check. Reconciles a widely repeated podcast statement against the primary regulatory record. Verdict: premature.

What was said

On February 27, 2026, on The Joe Rogan Experience (#2461), HHS Secretary Robert F. Kennedy Jr. said he expected "about 14" restricted peptides — BPC-157 among them — to move from Category 2 back to Category 1 "within a couple of weeks," restoring the pathway for licensed compounding pharmacies to prepare them so consumers could obtain them from "ethical suppliers" rather than anonymous online vendors S1.

What the record shows

• On FDA's compounding bulk-substances framework, BPC-157 sits in the "nominated but withdrawn" portion of Category 2 — substances that "may present significant safety risks." Removal from Category 2 is not the same as placement on a Category 1 / 503A Bulks List, and does not by itself make a substance eligible for compounding S2.
• Eligibility for the 503A Bulks List for these peptides is pending: the FDA Pharmacy Compounding Advisory Committee is scheduled to discuss BPC-157, KPV, TB-500, MOTs-C (July 23) and Emideltide/DSIP, Semax, Epitalon (July 24), 2026 under public docket FDA-2025-N-6895 S3S4.
• Advisory-committee recommendations are non-binding, and any change in list status would follow FDA's own decision and applicable rulemaking — not the committee meeting alone S3S4.

Reconciliation

The accurate core of the claim is that the administration signaled intent and that FDA initiated a formal review process for these peptides S1S3. What makes the claim premature is the framing of a Category 1 restoration as imminent and effectively decided: the stated "couple of weeks" timeline did not produce a Category 1 move; as of this entry no peptide named has been placed on the 503A Bulks List, and the deciding step (the PCAC meeting and any FDA action after it) had not occurred S2S3S4. The claim also conflates two distinct regulatory states — removal from Category 2 versus eligibility to compound under 503A — which are not the same thing S2.

What would change this verdict

A PCAC recommendation and subsequent FDA action actually placing any of these peptides on the 503A Bulks List — the earliest signal being the July 23–24, 2026 meeting — or a Federal Register determination to that effect. If that happens, the relevant portion of the claim would move from premature toward partly-accurate or accurate, dated to the actual action S3S4.